Not a Member?
Email this page
Send the page ""
to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
High potential for abuse; prolonged use may lead to drug dependence. Misuse may cause sudden death and serious cardiovascular (CV) adverse reactions.
Treatment of attention-deficit hyperactivity disorder.
Adults: Individualize dose and administer at lowest effective dose. Amphetamine-Naive/Switching from Another Medication: 20mg qam. Switching from Amphetamine Immediate-Release (IR): Give the same total daily dose, qd. Titrate at weekly intervals as indicated.
Pediatrics: Individualize dose and administer at lowest effective dose. Switching from Amphetamine IR: Give the same total daily dose, qd. Titrate at weekly intervals as indicated. Amphetamine-Naive/Switching from Another Medication: 13-17 Yrs: Initial: 10mg qam. Titrate: May increase to 20mg/day after 1 week if symptoms are not controlled. 6-12 Yrs: Initial: 10mg qam or 5mg qam when lower initial dose is appropriate. Titrate: Adjust daily dosage in increments of 5mg or 10mg at weekly intervals. Max: 30mg/day.
Oral route. Give upon awakening; avoid pm doses due to potential for insomnia. Take with or without food. Take caps whole or sprinkle entire contents on applesauce. Consume sprinkled applesauce immediately without chewing the sprinkled beads. Do not divide the dose of a single cap or take anything <1 cap/day.
Cap, Extended-Release: 5mg, 10mg, 15mg, 20mg, 25mg, 30mg
Advanced arteriosclerosis, symptomatic CV disease, moderate to severe HTN, hyperthyroidism, glaucoma, agitated states, history of drug abuse, during or within 14 days following MAOI use.
Sudden death, stroke, and myocardial infarction (MI) reported in adults. Sudden death reported in children and adolescents with structural cardiac abnormalities or other serious heart problems. Avoid use in patients with known serious structural cardiac and heart rhythm abnormalities, cardiomyopathy, coronary artery disease (CAD), or other serious cardiac problems. May cause modest increase in BP and HR. May exacerbate symptoms of behavior disturbance and thought disorder in patients with preexisting psychotic disorder. Caution in patients with comorbid bipolar disorder; may cause induction of mixed/manic episode. May cause treatment-emergent psychotic/manic symptoms (eg, hallucinations, delusional thinking, mania) in children and adolescents without a prior history of psychotic illness or mania; consider discontinuation if such symptoms occur. Aggressive behavior or hostility reported; monitor for appearance or worsening. May cause long-term suppression of growth in children; may need to d/c if patients are not growing or gaining weight as expected. May lower convulsive threshold; d/c if seizures develop. Associated with peripheral vasculopathy, including Raynaud's phenomenon. Difficulties with accommodation and blurring of vision reported. Exacerbation of motor and phonic tics and Tourette's syndrome reported. May significantly elevate plasma corticosteroid levels or interfere with urinary steroid determinations. Where possible, interrupt occasionally to determine the need for continued therapy.
Dry mouth, loss of appetite, insomnia, headache, abdominal pain, weight loss, agitation, anxiety, N/V, dizziness, tachycardia, nervousness, asthenia, diarrhea, urinary tract infection.
See Contraindications. Avoid with GI alkalinizing agents (eg, sodium bicarbonate, antacids). Urinary alkalinizing agents (eg, acetazolamide, some thiazides) may increase blood levels and potentiate effects. GI acidifying agents (eg, guanethidine, reserpine, ascorbic acid) and urinary acidifying agents (eg, ammonium chloride, sodium acid phosphate, methenamine salts) may lower blood levels and efficacy. May reduce CV effects of adrenergic blockers. May counteract sedative effects of antihistamines. May antagonize effects of antihypertensives. May inhibit hypotensive effect of veratrum alkaloids. May delay intestinal absorption of phenobarbital, phenytoin, and ethosuximide. May enhance activity of TCAs or sympathomimetic agents. Increased d-amphetamine levels in the brain with desipramine or protriptyline and possibly other tricyclics. May potentiate analgesic effect of meperidine. May enhance the adrenergic effect of norepinephrine. Chlorpromazine and haloperidol may inhibit central stimulant effects. Lithium carbonate may inhibit anorectic and stimulatory effects. Norepinephrine may enhance the adrenergic effect. Use in cases of propoxyphene overdose may potentiate CNS stimulation and cause fatal convulsions. Monitor for changes in clinical effect when coadministered with proton pump inhibitors.
Category C, not for use in nursing.
Sympathomimetic amine; has not been established. Thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.
Absorption: Tmax=7 hrs. Distribution: Found in breast milk. Metabolism: CYP2D6 (oxidation); 4-hydroxy-amphetamine and norephedrine (active metabolites). Elimination: Urine (normal pH) (30-40%, unchanged; 50%, α-hydroxy-amphetamine derivatives). (20mg single dose) d-amphetamine: T1/2=10 hrs (adults), 11 hrs (13-17 yrs of age), 9 hrs (6-12 yrs of age). l-amphetamine: T1/2=13 hrs (adults), 13-14 hrs (13-17 yrs of age), 11 hrs (6-12 yrs of age).
Assess for advanced arteriosclerosis, symptomatic CV disease, moderate to severe HTN, hyperthyroidism, hypersensitivity or idiosyncrasy to sympathomimetic amines, glaucoma, agitation, history of drug abuse, psychiatric history, history of seizure, tics or Tourette's syndrome, hepatic/renal dysfunction, pregnancy/nursing status, and possible drug interactions.
Monitor for CV abnormalities, exacerbations of behavior disturbances and thought disorder, psychotic or manic symptoms, aggressive behavior, hostility, seizures, visual disturbances, exacerbation of motor and phonic tics and Tourette's syndrome, and other adverse reactions. Monitor BP and HR. Monitor height and weight in children. Observe carefully for signs and symptoms of peripheral vasculopathy; further clinical evaluation (eg, rheumatology referral) may be appropriate for certain patients.
Inform about benefits and risks of treatment, appropriate use, and about the potential for abuse/dependence. Advise about serious CV risks. Inform that treatment-emergent psychotic or manic symptoms may occur. Instruct to report signs/symptoms of peripheral vasculopathy, including Raynaud's phenomenon. Advise parents or guardians of pediatric patients to monitor growth and weight during treatment. Advise to notify physician if pregnant or planning to become pregnant. Advise to avoid breastfeeding. Advise to use caution when engaging in potentially hazardous activities (eg, operating machinery or vehicles).
25°C (77°F); excursions permitted to 15-30°C (59-86°F).